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Abstract 
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged from China in Decem‑
ber 2019 and has presented as a substantial and serious threat to global health. We aimed to describe the clinical, 
epidemiological, and laboratory findings of patients in Saudi Arabia infected with SARS‑CoV‑2 to direct us in helping 
prevent and treat coronavirus disease 2019 (COVID‑19) across Saudi Arabia and around the world.
Materials and methods: Clinical, epidemiological, laboratory, and radiological characteristics, treatment, and out‑
comes of pediatric and adult patients in five hospitals in Riyadh, Saudi Arabia, were surveyed in this study.
Results: 401 patients (mean age 38.16 ± 13.43 years) were identified to be SARS‑CoV‑2 positive and 80% of cases 
were male. 160 patients had moderate severity and 241 were mild in severity. The most common signs and symptoms 
at presentation were cough, fever, fatigue, and shortness of breath. Neutrophil and lymphocyte counts, aspartate 
aminotransferase, C‑reactive protein, and ferritin were higher in the COVID‑19 moderate severity patient group. Mild 
severity patients spent a shorter duration hospitalized and had slightly higher percentages of abnormal CT scans and 
X‑ray imaging.
Conclusions: This study provides an understanding of the features of non‑ICU COVID‑19 patients in Saudi Arabia. 
Further national collaborative studies are needed to streamline screening and treatment procedures for COVID‑19.
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Background
In late 2019, a few unidentified pneumonia patients were 
found to have a formerly unfamiliar infection of a sub-
coronavirus, that was labeled 2019-novel coronavirus 
(2019-nCoV) [1]. This was later labeled by the World 
Health Organization (WHO) as severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and the disease 
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Many countries have started their safety measures and 
started screening people coming into their country. Saudi 
Arabia started its precautions and implemented screen-
ing for travelers, along with an international travel ban 
until the disease is more controlled. A governmental 
move followed by several decisions was made to prevent 
the outbreak. Along with other guidelines, the Ministry 
of Health and the Saudi Center for Disease Prevention 
and Control published the Coronavirus Infection Guide-
lines [3] that were designed to promptly detect and treat 
COVID-19. As of August 24, 2020, the total reported 
confirmed COVID-19 cases have reached more than 
308,600 including more than 3600 deaths within Saudi 
Arabia, and the increasing number of cases geographi-
cally with fatalities has raised multiple concerns [4]. Not-
withstanding the rising amount of confirmed cases, the 
clinical data of SARS-CoV-2 patients in Saudi Arabia are 
insufficient.
Human to human transmission of the virus is now 
clear and well reported in many countries [5]. The mode 
of transmission for SARS-CoV-2 is mostly seen through 
respiratory droplets, direct contact with an infected indi-
vidual, or by touching a contaminated surface or object 
[6, 7]. Precautions have to be taken including effective 
frequent handwashing and individuals should be keep-
ing ≥ 6 feet away from other people are crucial in helping 
reduce the risk of infection and to halt the transmission 
cycle [8]. Currently, researchers from many countries are 
conducting clinical trials to produce or evaluate potential 
treatments, including a local ongoing trial to test the effi-
cacy of convalescent plasma in our population [6]. How-
ever, we still do not have any approved treatments or fully 
ready vaccines for COVID-19 [7]. COVID-19 patients 
initially present with mostly fever, dry cough, and fatigue. 
A variety of less abundant symptoms may occur such 
as anosmia, hypogeusia, diarrhea, and headache [8]. In 
more severe cases, patients may have chest pain, dysp-
nea, and even loss of speech or movement [8]. The most 
challenging issue with COVID-19 is that a large fraction 
of infected individuals are asymptomatic carriers, which 
can also transmit SARS-CoV-2 to other individuals [9]. 
We aimed to describe the clinical, epidemiological, and 
laboratory features of patients in Saudi Arabia infected 
with SARS-CoV-2 to direct us in helping prevent and 
treat coronavirus disease 2019 (COVID-19) across Saudi 
Arabia and around the world.
Materials and methods
Study population
Between April 22nd and May 22nd, 2020, we enrolled 
401 patients with COVID-19 at four branches of our 
private tertiary care hospital and one private hospital in 
Riyadh, Saudi Arabia.
Design
A large team was assembled to collect data retrospec-
tively from electronic medical records, and each record 
was then reviewed independently by four trained 
doctors.
Data collection
Data gathered included demographic data, past medi-
cal history, symptoms, laboratory values, chest X-rays 
and CT scans, and the treatment provided. Laboratory 
values included complete blood counts, biochemistries, 
biomarkers for organ function, and analysis of immu-
nological responses. Patients’ severities were classified 
based on the “Chinese Clinical Guidance for COVID-19 
Pneumonia Diagnosis and Treatment” published by the 
Chinese National Health Commission [10]. Mild clinical 
symptoms or asymptomatic with no signs of pneumonia 
in imaging were defined as “Mild”; and "Moderate" were 
characterized as having signs of pneumonia on imaging, 
and fever or clinical respiratory tract manifestations. The 
therapeutic principles comprised of general supportive 
therapy; active control over high fever; oxygen uptake if 
necessary; antiviral treatments; and monitoring of liver, 
kidney, myocardial, and lung functions. Several other 
investigational therapies evaluated for COVID-19 treat-
ment (hydroxychloroquine, azithromycin, oseltamivir, 
vitamin C, vitamin E, ceftriaxone, and enoxaparin), were 
also included. The time taken to become SARS-CoV-2 
PCR negative, duration of hospitalization, and treatment 
outcomes were recorded.
Statistical analysis
Continuous variables were presented as mean (± SD) 
and categorical variables were written as number (%). We 
compared proportions for categorical variables between 
groups using Chi-square test. When values were nor-
mally distributed, we used independent group t-tests to 
compare means of continuous variables between groups; 
else, we used the Mann–Whitney U test. To test whether 
the observed heart rate, PR interval, QRS interval, and 
QTc interval during hydroxychloroquine treatment were 
statistically distinct from the baseline, paired samples 
t-test was used. We evaluated a p-value less than 0.05 as 
statistically significant. All data analyses were completed 
with SPSS version 25.
Ethical considerations
This study was approved by the Institutional Review 
Board of Dr. Sulaiman Al Habib Medical Group and fol-
lowed the Declaration of Helsinki. As patient data were 
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deidentified and this was a retrospective study, written 
consent was not required.
Results
Among the 401 hospitalized patients, 241 (60.1%) cases 
were separated into the mild group and 160 (39.9%) cases 
were split into the moderate group. The mean age of 
patients was 38.16 ± 13.43 years (median: 36.00) and 321 
(80%) cases were male. Of these cases, only 4% of those 
patients were under 18 years of age. The main ethnicities 
represented in our cohort were Asian (49.9%) and Mid-
dle Eastern (48.1%), and, in lower proportions, African 
(1.2%) and European (0.7%). Most patients were treated 
at Habib Medical Group (HMG) Suwaidi Hospital 
(26.2%), HMG Rayan Hospital (25.4%), and Al Hammadi 
Hospital (24.2%) (Table 1).
Compared to mild patients, moderate patients were 
older in age (mean age 37.32 ± 13.6 years (median: 36.00) 
vs 39.43 ± 13.1 (median: 39.00); p = 0.112) and were more 
likely to have underlying comorbidities, such as hyper-
tension (33 [20.6%] vs 26 [10.8%]), diabetes (20 [12.5%] 
vs 20 [8.3%]), chronic heart disease (7 [4.4%] vs 4 [1.7%]), 
chronic lung disease (6 [3.8%] vs 9 [3.7%]), obesity class 
I (18 [11.3%] vs 16 [6.6%]), obesity class II (5 [3.1%] vs 5 
[2.1%]), dyslipidemia (11 [6.9%] vs 8 [3.3%]), and preg-
nancy (1 [0.6%] vs 0). Mild COVID-19 severity patients 
smoked more tobacco than moderate severity cases (7.9% 
vs 5%), mostly smoking 10–15 cigarettes per day (47.3%) 
or 20 cigarettes per day (42.1%) (Table 1).
The most common signs and symptoms at the onset 
of illness were cough (215 [53.6%]), fever ≥ 38  °C upon 
admission (146 [36.4%]), fatigue (104 [25.9%]), shortness 
of breath (90 [22.4%]), sore throat (88 [21.9%]), head-
ache (65 [16.2%]), fever ≥ 38  °C during hospitalization 
(62 [15.5%]) and muscle pain (57 [14.2%]). Less common 
symptoms were joint pain (36 [9%]), diarrhea (70 [7.5%]), 
sputum production (30 [7.5%]), rhinorrhea (29 [7.2%]), 
nausea (26 [6.5%]), dysgeusia (22 [5.5%]), and anosmia 
(19 [4.7%]) (Table 1).
Abnormal laboratory findings in mild and moderate 
severity patients were C-reactive protein (CRP) (11.1 
vs 28.6  mg/L), D-dimer (0.57 vs 0.69  mg/L) and fer-
ritin (201.6 vs 445.2  ng/ml). Neutrophil count (4.4 vs 
4.0 × 109/L), lymphocyte count (3.3 vs 2.6 × 109/L), ala-
nine aminotransferase (39.4 vs 35.8 U/L), aspartate ami-
notransferase (34.9 vs 28.4 U/L), CRP (28.6 vs 11.1 mg/L), 
D-dimer (0.69 vs 0.57  mg/L), and ferritin (445.2 vs 
290.5  ng/ml) were higher in the COVID-19 moderate 
severity patient group. Some laboratory tests differed 
significantly between the two severity groups, including 
increased aspartate aminotransferase (p ≤ 0.001), raised 
CRP (p ≤ 0.001), high levels of D-dimer (p = 0.028) and 
ferritin (p ≤ 0.001) (Table 1).
Generally, mild severity patients had slightly higher 
percentages of abnormal CT scans (52.2% vs 47.7%) and 
abnormal X-ray imaging (52.1% vs 47.8%) compared to 
moderate severity cases (Table  1). Over the course of 
treatment, moderate severity patients required supple-
mentary oxygen via a nasal cannula in comparison to 
the mild severity patient group (16.3% vs 2.5%) and were 
administered higher amounts of hydroxychloroquine 
(26.9% vs 9.5%), azithromycin (74.4% vs 30.7%), oseltami-
vir (54.4% vs 19.5%), vitamin C (5.6% vs 3.7%), vitamin E 
(5.6% vs 3.3%), ceftriaxone (15% vs 7.1%), and enoxaparin 
(2.5% vs 0.4%) (Table 1).
Compared with the moderate severity group, the mean 
days taken to become SARS-CoV-2 PCR-negative was 
a bit higher in the mild severity patient group (mean 
3.11 days vs 3.0 days, p = 0.845; respectively). Mild sever-
ity patients spent a shorter duration of hospitalization 
(mean 7.37  days vs 9.71  days, p ≤ 0.001; respectively). 
Mild severity patient group had better prognosis out-
comes in terms of hospitalization (76.8% vs 81.3%), 
transfer (3.3% vs 6.3%), and discharge (19.9% vs 12.5%) 
(Table 1).
An aggregate of 63 patients had both an ECG recording 
at baseline and days 3–5 post initiation of hydroxychloro-
quine therapy. Table 2 shows the mean QTc interval prior 
to and throughout hydroxychloroquine treatment in all 
mild and moderate COVID-19 patients. Hydroxychloro-
quine treatment ensued in a mean QTc prolongation of 
5.93 ms in all patients (95% CI 13.35–1.49 ms; p = 0.113) 
using computerized interpretation. Those receiving 
hydroxychloroquine in the mild COVID-19 severity 
group had a greater mean difference in QTc interval pro-
longation (8.5 [− 20.22 to 3.22] ms; p = 0.143) compared 
with those receiving hydroxychloroquine in the moderate 
severity group (2.5 [− 11.87 to 6.87] ms; p = 0.569). Not 
any of these patients had a prolonged interval ahead of 
the initiation of hydroxychloroquine therapy and none 
were using antiarrhythmic drugs simultaneously.
Discussion
This is a large cohort study of hospitalized patients with 
SARS-CoV-2 in Saudi Arabia. There was no significant 
disparity in the ratio of female and male patients, and 
infection in children was exceptionally low, which was 
consistent with the findings of other studies [1, 8, 9].
The median age of our cohort was 36  years, which is 
identical to the discoveries of a national study, indicating 
that COVID-19 affects a younger age group in Saudi Ara-
bia compared to the rest of the world [11]. This might be 
attributed mainly to the differences in the inclusion crite-
ria and the population age groups in our study. However, 
all the age groups might have been infected, including 
those younger than 2 and older than 80. Our findings 
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Table 1 Clinical and epidemiological features of COVID-19 patients
Epidemiological data Total (n = 401) Mild cases (n = 241) Moderate cases (n = 160) p-value*
Female patients 80 (20%) 50 (20.7) 30 (18.8) 0.624
Male patients 321 (80%) 191 (79.3) 130 (81.3)
Age, years (SD, range) 38.16 (13.43, 1–88) 37.32 (13.6, 1–83) 39.43 (13.1, 1–88) 0.112
  Age ≤ 18 years 16 (4%) 12 (75) 4 (25)
Race
  Middle eastern 193 (48.1) 104 (43.2) 89 (55.6) 0.06
  Asian 200 (49.9) 133 (55.2) 67 (41.9)
  African 5 (1.2) 2 (0.8) 3 (1.9)
  European 3 (0.7) 2 (0.8) 1 (0.6)
Admission location
  HMG Suwaidi Hospital 105 (26.2) 83 (34.4) 22 (13.8)  ≤ 0.001
  HMG Rayan Hospital 102 (25.4) 71 (29.5) 31 (19.4)
  HMG Takhassusi Hospital 44 (11) 33 (13.7) 11 (6.9)
  HMG Olaya Hospital 53 (13.2) 30 (12.4) 23 (14.4)
  Al Hammadi Hospital 97 (24.2) 24 (10) 73 (45.6)
  Frequency of PCR performed (SD, range) 2.56 (1.51, 1–10) 2.57 (1.48) 2.55 (1.56) 0.710
Symptoms
 Cough 215 (53.6) 102 (42.3) 113 (70.6)  ≤ 0.001
 Fatigue 104 (25.9) 50 (20.7) 54 (33.8) 0.004
 Headache 65 (16.2) 38 (15.8) 27 (16.9) 0.768
 Diarrhea 30 (7.5) 17 (7.1) 13 (8.1) 0.690
 Shortness of breath 90 (22.4) 32 (13.3) 58 (36.3)  ≤ 0.001
Body temperature, °C
 Fever upon admission was ≥ 38 °C 146 (36.4) 0 146 (91.3)  ≤ 0.001
 Fever during hospitalization was ≥ 38 °C 62 (15.5) 0 62 (38.8)  ≤ 0.001
 Sore throat 88 (21.9) 32 (13.3) 58 (36.3) 0.052
 Muscle pain 57 (14.2) 22 (9.1) 35 (21.9)  ≤ 0.001
 Joint pain 36 (9) 12 (5) 24 (15) 0.001
 Nausea 26 (6.5) 16 (6.6) 10 (6.3) 0.877
 Rhinorrhea 29 (7.2) 18 (7.5) 11 (6.9) 0.822
 Dysgeusia 22 (5.5) 13 (5.4) 9 (5.6) 0.921
 Vomiting 16 (4) 9 (3.7) 7 (4.4) 0.748
 Anorexia 13 (3.2) 9 (3.7) 4 (2.5) 0.494
 Chest pain 3 (0.7) 2 (0.8) 1 (0.6) 0.816
 Abdominal pain 4 (1) 3 (1.2) 1 (0.6) 0.541
 Sputum production 30 (7.5) 13 (5.4) 1 (0.6) 0.051
 Anosmia 19 (4.7) 13 (5.4) 6 (3.8) 0.448
 Hyposmia 3 (0.7) 2 (0.8) 1 (0.6) 0.816
 Sweating 2 (0.5) 2 (0.8) 0 0.248
Comorbidities
 Hypertension 59 (14.7) 26 (10.8) 33 (20.6) 0.006
 Hyperglycaemia 40 (10) 20 (8.3) 20 (12.5) 0.169
 Chronic kidney disease 1 (0.2) 1 (0.4) 0 0.415
 Chronic heart disease 11 (2.7) 4 (1.7) 7 (4.4) 0.103
 Chronic lung disease 15 (3.7) 9 (3.7) 6 (3.8) 0.994
Obesity
  Class I 34 (8.5) 16 (6.6) 18 (11.3) 0.220
  Class II 10 (2.5) 5 (2.1) 5 (3.1) –
  Class III 2 (0.5) 2 (0.8) 0 –
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Table 1 (continued)
Epidemiological data Total (n = 401) Mild cases (n = 241) Moderate cases (n = 160) p-value*
  Not obese 355 (88.5) 218 (90.5) 137 (85.6) –
Smoking
  Non‑smoker 366 (91.3) 216 (89.6) 150 (93.8) 0.349
  Smoker 27 (6.7) 19 (7.9) 8 (5) –
No. of cigarettes per day
 10–15 cigarettes per day 11 (40.7) 9 (47.3) 2 (25) –
 20 cigarettes per day 13 (48.1) 8 (42.1) 5 (62.5) –
 30–40 cigarettes per day 3 (11.1) 2 (10.5) 1 (12.5) –
 Former smoker 8 (2) 6 (2.5) 2 (1.3) –
 Dyslipidemia 19 (4.7) 8 (3.3) 11 (6.9) 0.101
 Pregnant 1 (0.2) 0 1 (0.6) 0.182
 Immunocompromised status 1 (0.2) 1 (0.4) 0 0.415
Laboratory tests
 White cell count, × 109/L 6.56 (3.7) 6.84 (2.3) 6.14 (5.2) 0.069
 Platelet count, × 109/L 236.7 (75.3) 250.6 (79.3) 215.9 (63.7)  ≤ 0.001
 Neutrophil count, × 109/L 4.2 (5) 4.0 (4.0) 4.4 (6.2) 0.425
 Lymphocyte count, × 109/L 2.9 (6.1) 2.63 (2.7) 3.3 (9.1) 0.346
 Alanine aminotransferase, U/L 37.29 (28.8) 35.8 (26.2) 39.4 (32.1) 0.399
 Aspartate aminotransferase, U/L 31.1 (20.5) 28.4 (18.6) 34.9 (22.4)  ≤ 0.001
 C‑reactive protein, mg/L 16.99 (32.4) 11.1 (28.4) 28.6 (36.5)  ≤ 0.001
 D‑dimer, mg/L 0.6 (1.6) 0.57 (0.98) 0.69 (2.1) 0.028
 Lactate concentration, mmol/L 1.5 (0.5) 1.5 (0.57) 1.45 (0.5) 0.590
 Ferritin (ng/ml) 290.5 (409.6) 201.6 (275.0) 445.2 (541.2)  ≤ 0.001
Radiography
 Chest CT
  Abnormal 67 (16.7) 35 (52.2) 32 (47.7) 0.239
  Normal 3 (0.7) 0 3 (100)
 Chest X‑ray
  Abnormal 140 (34.9) 73 (52.1) 67 (47.8) 0.101
  Normal 193 (48.1) 118 (61.1) 75 (38.8)
Treatment
 Oxygen inhalation 32 (8) 6 (2.5) 26 (16.3)  ≤ 0.001
 Amount of oxygen provided (L) 4.03 (2.83) 4.8 (4.4) 3.8 (2.3) 0.746
 Hydroxychloroquine 66 (16.5) 23 (9.5) 43 (26.9)  ≤ 0.001
 Azithromycin 193 (48.1) 74 (30.7) 119 (74.4)  ≤ 0.001
 Oseltamivir 134 (33.4) 47 (19.5) 87 (54.4)  ≤ 0.001
 Vitamin C 18 (4.5) 9 (3.7) 9 (5.6) 0.371
 Vitamin E 17 (4.2) 8 (3.3) 9 (5.6) 0.262
 Ceftriaxone 41 (10.2) 17 (7.1) 24 (15) 0.16
 Enoxaparin 5 (1.2) 1 (0.4) 4 (2.5) 0.085
Prognosis
  Hospitalization 315 (78.6) 185 (76.8) 130 (81.3) 0.074
  Transferred 18 (4.5) 8 (3.3) 10 (6.3)
  Discharged 68 (17) 48 (19.9) 20 (12.5)
Days taken to be SARS‑CoV‑2 PCR‑negative, (SD, range) 3.08 (1.9, 1–11) 3.11 (1.9, 1–11) 3.0 (2.0, 1–10) 0.845
Days of hospitalization, (SD, range) 8.3 (6, 1–42) 7.37 (5.5, 1–34) 9.71 (6.5, 1–42)  ≤ 0.001
COVID-19 = coronavirus disease 2019. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Data are n (%) or mean (SD), unless otherwise indicated
* p values suggest the disparity between pediatric and adult patients with moderate clinical type with pneumonia and mild clinical type (asymptomatic or upper 
respiratory infection)
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concur with previous studies, showing that patients 
infected with SARS-CoV-2 may present primarily with 
cough, fever ≥ 38  °C, lethargy, sore throat, shortness of 
breath, headache, and muscle pain with accompanying 
symptoms of sputum production, rhinorrhea, diarrhea, 
dysgeusia and anosmia like common cold [8, 9].
Mild severity patients may present without a fever and 
without signs of pneumonia; moderate patients usually 
have a fever ≥ 38  °C or respiratory symptoms, mainly 
shortness of breath, cough, and sore throat. There are 
many similarities between COVID-19, SARS-CoV, 
and new microorganisms such as avian influenza virus 
H7N9. However, there are also key differences. COVID-
19 cases can vary from mild to moderate or even severe, 
while SARS cases or avian influenza virus H7N9, in gen-
eral, were more severe [12]. Unlike SARS-CoV infec-
tions which usually result in a high-grade fever at the 
early onset of infection [12], some COVID-19 patients 
included in our report presented with atypical symptoms 
and only low-grade fever and a long incubation period 
leading to a higher potential for COVID-19 viral trans-
mission and greater infectiousness.
In our study, abnormal chest X-ray findings were more 
than twice as common as chest CT abnormalities in all 
patients (34.9% vs 16.7%). Since some of the mild severity 
patients were asymptomatic, it has been proposed that 
a CT examination should be the earliest choice in the 
screening and diagnosis of COVID-19. This is because 
the sensitivity of CT scan for SARS-CoV-2 was found to 
be 98%, compared to the RT-PCR sensitivity of 71% [13]. 
Swift detection of COVID-19 is vital for disease ther-
apy and control, and hence, a chest CT may be a more 
dependable, useful, and quick method to diagnose and 
evaluate COVID-19 [14].
As Al-Omari, et  al. had recently pointed out, we 
deemed it necessary to investigate the laboratory and 
radiological features of COVID-19 patients in the Saudi 
population [15]. Our mild and moderate COVID-19 
patients had elevated inflammatory markers (e.g., CRP, 
D-dimer, and ferritin), similar to cytokine release syn-
drome, with persistent fevers [16, 17]. A recent study 
from Saudi Arabia also had similar findings with higher 
CRP, D-dimer, ferritin, and glucose levels in moderate 
severity patients [3]. At the initial stage of COVID-19, 
the level of inflammation and lung lesions were positively 
linked with CRP levels, and thus, CRP levels could sig-
nify disease severity and were suggested to be utilized 
as a major marker for disease monitoring [18]. Recently, 
Wang, et  al. also demonstrated that a CRP finding 
of > 26.9  mg/L could be used as a predictive marker for 
aggravating severity of COVID-19 [19]. An elevated level 
of D-dimer in patients with COVID-19 disease may pro-
voke an emergent thrombotic complication and may due 
to the hyperactivation of the coagulation cascade. There 
is a systemic inflammatory response triggered by viral 
infections that can cause an imbalance between anticoag-
ulant and procoagulant homeostatic processes [20]. Fer-
ritin is a fundamental mediator of immune dysregulation 
and contributes to the cytokine storm via direct immune-
suppressive and pro-inflammatory effects [21].
Higher neutrophil absolute count has been related to 
a greater severity in COVID-19 as well as lymphopenia 
[21, 22]; higher levels of lymphocytes has not. Moreover, 
higher levels of liver enzymes were more manifested in 
the moderate patients compared to the mild cases, indi-
cating that liver inflammation and liver damage in mod-
erate patients are more evident [1]. However, additional 
studies in Saudi Arabia are required to precisely identify 
which laboratory markers can potentially predict out-
comes of COVID-19 patients in the Saudi population.
The ideal approach to the treatment of SARS-CoV-2 is 
uncertain and is based on limited data and evolves rap-
idly as clinical data emerge. Lack of a defined optimal 
management plan for COVID-19 disease results in the 
use of various treatment options and adjuvant therapies 
during hospital stay. For patients with non-severe dis-
ease, care is primarily supportive, with close monitoring 
for disease progression.  Supportive measures offered to 
all patients in this study included the prevention of sec-
ondary infections, respiratory support, circulatory sup-
port, and preservation of renal, hepatic, and neurological 
function. In addition to the implementation of the basic 
principles of critical care medicine, patients received 
pharmacologic prophylaxis for venous thromboembo-
lism. The frequencies of the supportive measures used 
for mild and moderate severity patient groups were not 







treatment (ms) (95% CI)
Mean QTc 
during hydroxychloroquine 
treatment (ms) (95% CI)
Mean difference (ms) (95% 
CI)
p-value
Computer interpreted All 400.68 (384.99–416.36) 414.06 (389.4–423.81) 5.93 (− 13.35 to 1.49) 0.113
Mild 414.06 (392.61–435.52) 422.56 (397.85–447.28) 8.5 (− 20.22 to 3.22) 0.143
Moderate 382.83 (360.85–404.81) 385.33 (364.89–405.77) 2.5 (− 11.87 to 6.87) 0.569
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similar, but no conclusions can be made about efficacy. 
Hydroxychloroquine was used partly to treat the patients 
in both groups even though its routine use is not sug-
gested outside the circumstances of a clinical trial given 
the lack of clear benefit from limited data and potential 
for cardiotoxicity [23, 24]. Given the lack of clear bene-
fit and potential for toxicity, use of hydroxychloroquine 
in hospitalized patients is not suggested [25]. However, 
hydroxychloroquine was used when the data about its 
benefit were scarce, considering that we have accumu-
lated enough information now to ensure that hydroxy-
chloroquine is not effective as a COVID-19 treatment or 
prophylaxis.
Our analysis demonstrates that therapy of COVID-19 
patients with hydroxychloroquine resulted in a non-sta-
tistically significant effect on QTc interval. Hydroxychlo-
roquine inhibits voltage-gated sodium and potassium 
channels, prolonging the QT interval, and is also struc-
turally analogous to the class IA antiarrhythmic quini-
dine [8]. Changes in QTc and prolongation findings due 
to hydroxychloroquine use aligned with previous studies 
of substantial QTc prolongation in 11–23% of patients 
[26, 27]. While the addition of azithromycin to hydroxy-
chloroquine might have been implicated in QTc prolon-
gation [28], it is still conceivable that the genuine degree 
of QTc prolongation associated with hydroxychloroquine 
was estimated imprecisely, given patient severity and 
characteristics variation and a limited follow-up period.
It is pertinent to recognize some limitations of this 
study. First, the retrospective study design could have 
introduced potential reporting bias due to reliance on 
clinical case records. Second, without a control group, we 
were unable to determine that hydroxychloroquine and 
azithromycin increases cardiotoxic risk; but, compared 
with solely hydroxychloroquine, changes in QTc differ-
ences were likely related to the addition of azithromy-
cin. Furthermore, we were not able to provide details on 
the radiological characters of our SARS-CoV-2-infected 
patients. Moreover, many of the study patients are still 
hospitalized at the time of the writing of this manuscript. 
Consequently, there may have been some partiality 
regarding the prognosis of the patients. Finally, some fol-
low-up data were unavailable. Clinical follow-up data for 
patients after recovery from SARS-CoV-2 infection could 
be used to examine longer-term functional and psycho-
logical abnormalities.
Conclusions
Although fever, cough, fatigue, and shortness of breath 
are common symptoms, more than half of patients have 
neither clear signs nor abnormal radiological findings. 
The large number of asymptomatic patients suggests dif-
ficulty in identifying some COVID-19 patients. In con-
trast to the mild cases, the moderate ones had higher 
neutrophil counts, lymphocyte counts, alanine ami-
notransferase, aspartate aminotransferase, CRP, and 
higher levels of ferritin, but lower levels of D-dimer, lac-
tate concentrations, and platelet counts. Chest CT scans 
ought to be the earliest choice for the screening and 
diagnosis of COVID-19 due to higher sensitivity. There 
are currently no fully certified treatments for COVID-19 
and with the help of ongoing clinical trials and further 
international collaborative studies, we will be able to 
develop first-class screening and treatment protocols.
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